BLTE — Belite Bio, Inc Stock Price, Chart & AI Report

Neutral Dec 2, 2025 • 03:37 UTC GlobeNewswire Inc. • Jennifer Wu / Julie Fallon

Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares

Belite Bio has priced a public offering of 2,272,727 American Depositary Shares at $154.00 per share, expecting to raise approximately $350 million to fund commercialization preparation, pipeline development, and general corporate purposes.

BLTE MS MSPA MSPE public offering ADSs drug development retinal diseases

Sentiment note

The company is raising capital through a standard public offering to support its ongoing clinical development and commercialization efforts, indicating a strategic financial move without strong positive or negative implications

Positive Dec 1, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight

The geographic atrophy market is expected to grow significantly due to rising global prevalence, aging populations, and emerging therapies targeting this advanced form of age-related macular degeneration.

APLS ALPMY BLTE geographic atrophy macular degeneration complement inhibitor therapies ophthalmology emerging treatments

Sentiment note

Received regulatory approval for Phase III PHOENIX trial and advancing innovative oral drug Tinlarebant

Positive Nov 17, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Dry Age-related Macular Degeneration Market Poised for Rapid Growth During the Forecast Period (2025–2034) Amid Expanding Treatment Landscape | DelveInsight

The dry AMD market is expected to grow significantly by 2034, driven by emerging therapies, increasing diagnosis rates, and novel treatment approaches targeting geographic atrophy.

BLTE JNJ dry AMD macular degeneration geographic atrophy ophthalmology emerging therapies

Sentiment note

Conducting global Phase III PHOENIX study for tinlarebant, with regulatory approval for trial in the UK

Positive Nov 2, 2025 • 14:00 UTC GlobeNewswire Inc. • Belite Bio

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio received conditional marketing authorization from the UK's MHRA for Tinlarebant, a potential treatment for Stargardt disease, based on interim Phase 3 DRAGON trial results. The company expects final topline data in Q4 2025.

BLTE Tinlarebant Stargardt disease MHRA Phase 3 DRAGON trial marketing authorization

Sentiment note

Company received regulatory support for its novel drug, indicating promising clinical trial results and potential breakthrough in treating Stargardt disease

Positive Oct 15, 2025 • 12:00 UTC GlobeNewswire Inc. • Belite Bio

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

Belite Bio received priority review from China's NMPA for Tinlarebant, a novel oral therapy for treating Stargardt disease, based on positive interim Phase 3 trial results. The company expects final topline data in Q4 2025.

BLTE Stargardt disease Tinlarebant NMPA Phase 3 trial retinal disease

Sentiment note

Received priority review from NMPA, positive interim trial results, potential first treatment for Stargardt disease, advancing drug development

Neutral Oct 2, 2025 • 13:06 UTC Investing.com • Nathan Reiff

3 Lesser-Known Healthcare Names With Major Upside in Store

The global healthcare market is expected to grow significantly, with three lesser-known companies showing promising potential: Sanuwave Health, Amneal Pharmaceuticals, and Belite Bio, each offering unique strengths in medical technology and pharmaceuticals.

SNWV AMRX BLTE healthcare medical technology pharmaceuticals investment growth

Sentiment note

Pre-revenue clinical stage biotech with promising drug candidates, $150 million cash reserve, and four out of five analysts rating it a Buy with 32% potential upside

Positive Sep 8, 2025 • 12:00 UTC GlobeNewswire Inc. • Belite Bio

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Belite Bio secured a $125 million private placement financing led by RA Capital Management, with potential for an additional $150 million through warrant exercises, to support its clinical-stage drug development for retinal degenerative diseases.

BLTE MS MSPA MSPE private placement financing retinal diseases tinlarebant

Sentiment note

Raised significant capital from leading healthcare investors, received validation for scientific approach, and plans to advance drug development for retinal diseases

Neutral Aug 7, 2025 • 12:00 UTC GlobeNewswire Inc. • Belite Bio, Inc

Belite Bio Announces Registered Direct Offering of $15 Million

Belite Bio has entered into a securities purchase agreement to sell 230,770 American Depositary Shares and accompanying warrants at $65 per share, expecting to raise approximately $15 million for working capital and general corporate purposes.

BLTE securities offering ADSs warrants financing drug development

Sentiment note

The company is raising capital through a registered direct offering, which is a standard financing method for clinical-stage companies to fund operations and research

Positive Jul 2, 2025 • 07:00 UTC GlobeNewswire Inc. • Belite Bio

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

Belite Bio completed enrollment in a global Phase 3 trial evaluating Tinlarebant, an oral medication for treating geographic atrophy in dry age-related macular degeneration, with 500 subjects across 8 countries.

BLTE geographic atrophy dry age-related macular degeneration clinical trial Tinlarebant retinal disease

Sentiment note

Completed global trial enrollment, advancing promising drug candidate with potential to address unmet medical need in retinal disease treatment

Neutral May 13, 2025 • 07:00 UTC GlobeNewswire Inc. • N/A

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

Deutsche Bank is hosting a virtual investor conference on May 15, 2025, featuring live webcasts from various international companies with American Depositary Receipt (ADR) programs in the United States.

VIOT CLCGY HCM COE Deutsche Bank Depositary Receipts Virtual Investor Conference ADR

Sentiment note

The article simply lists the company as a participant in the conference, without providing any additional information about the company's performance or outlook.

Neutral May 13, 2025 • 00:00 UTC GlobeNewswire Inc. • N/A

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

International companies with American Depositary Receipt (ADR) programs in the United States will present live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025.

VIOT CLCGY HCM COE ADR international companies investor conference webcast

Sentiment note

The article simply lists the company as a participant in the conference without any additional information about its performance or outlook.

Positive Mar 17, 2025 • 10:00 UTC GlobeNewswire Inc. • Belite Bio, Inc

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Belite Bio announced positive progress in its clinical trials for Stargardt disease and geographic atrophy, with the DRAGON trial proceeding without modification and the PHOENIX trial ongoing. The company also raised $15 million in a registered direct offering.

BLTE Belite Bio Tinlarebant Stargardt disease Geographic Atrophy DRAGON trial PHOENIX trial

Sentiment note

The article highlights Belite Bio's progress in its clinical trials, the successful completion of a $15 million financing, and the company's overall positive outlook.